Omzo vs Hers: Compounded Semaglutide vs Brand Wegovy Options
Omzo vs Hers is a choice between compounded medication access with clinician-guided plans and branded FDA-approved Wegovy with a personalized care team. Early verdict: choose Omzo if you want clinician-guided access to compounded semaglutide starting at $179; choose Hers if you prefer FDA-approved Wegovy from $149/mo and ongoing dose check-ins.
Explore Omzo clinician-guided plans
Key difference 1: Compounded medications versus FDA-approved brand
Omzo emphasizes a compounded medication program: compounded semaglutide and tirzepatide prepared by a state licensed sterile compounding pharmacy. The Omzo source explicitly states these compounded drugs are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. By contrast, Hers highlights FDA-approved Wegovy, a brand-name semaglutide, and states it does not offer compounded medications.
Key difference 2: Pricing structure and starting costs
Both providers publish starting prices but with different structures. Omzo lists semaglutide starting at $179 and tirzepatide starting at $279, with medication costs included in fees collected by Omzo. Hers lists Wegovy from $149/mo and injectable from $199/mo, but notes an active Hers Weight Loss Membership is required and membership and medication are billed separately.
Key difference 3: Clinical model and follow up
Omzo connects users with licensed U.S. medical providers who determine eligibility and prescribe based on clinical judgment; Omzo is not a medical practice and clinical services are provided by third party networks. Hers promotes a personalized care team with ongoing dose check-ins and emphasizes doctor-trusted, FDA-approved options. Both note that treatment is available only when a licensed clinician determines it is medically appropriate.
Key difference 4: What you receive and who fills prescriptions
Omzo states its primary program provides access to compounded medications produced in FDA-registered facilities but not FDA-approved, and that if a branded medication is prescribed the patient is responsible for filling it at their chosen pharmacy. Hers provides brand-name Wegovy as an option and says name brand medication is not compounded.
Comparison table
| Criteria | Omzo | Hers |
|---|---|---|
| Medication type | Compounded semaglutide & tirzepatide (not FDA-approved) | FDA-approved Wegovy and other brand GLP-1s, not compounded |
| Starting price | Semaglutide starting at $179; tirzepatide starting at $279 | Wegovy from $149/mo; injectable from $199/mo (medication only) |
| Clinical model | Clinician-guided plans reviewed by licensed U.S. providers; third party networks | Personalized care team with ongoing dose check-ins |
| Regulatory note | Compounded medications are not FDA-approved | Offers FDA-approved Wegovy; no compounded products |
| Membership/fees | Medication costs included in Omzo fees; verify eligibility, renewal, state availability | Active Hers Weight Loss Membership required; membership and medication billed separately |
Other considerations from the sources
Omzo repeatedly notes results may vary, that it does not create a doctor patient relationship via its assessment, and that providers make the final determination to prescribe. It also states compounded medications offered by providers accessed through Omzo are produced in FDA-registered facilities but are not FDA-approved. Hers highlights that Wegovy and Zepbound are FDA-approved for weight loss and states that prescriptions are subject to clinician review and not available in all 50 states.
See Hers FDA-approved Wegovy plans
Safety and eligibility notes
Both sources emphasize eligibility is determined by a licensed clinician and that medication availability and state coverage may change. Omzo cautions that compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. Hers reiterates which branded options are FDA-approved and notes prescriptions require clinician determination.
Check Omzo eligibility and options
Final comparison and who each is best for
Omzo vs Hers comes down to a choice between compounded medication access and branded FDA-approved therapy with ongoing dose support. Omzo offers clinician-guided access to compounded semaglutide starting at $179 and tirzepatide starting at $279, while Hers offers FDA-approved Wegovy from $149/mo with a personalized care team and dose check-ins but requires an active membership for medication access.
Compare Hers membership and medication details
Choose Omzo if…
- You want clinician-guided access to compounded semaglutide or tirzepatide and accept that compounded medications are not FDA-approved.
- You prefer medication costs included in fees collected through the Omzo program and want fast discreet delivery options as described by Omzo.
Choose Hers if…
- You prefer FDA-approved brand-name Wegovy with a personalized care team and ongoing dose check-ins.
- You accept a membership requirement and separate billing for medication as described by Hers.
When thinking about Omzo vs Hers, confirm eligibility, medication details, total cost, renewal terms, and state availability with each provider before enrolling.